Welcome to our dedicated page for Celcuity SEC filings (Ticker: CELC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celcuity Inc. filings document formal disclosures for a clinical-stage biotechnology company developing targeted oncology therapies. Recent 8-K reports cover gedatolisib and VIKTORIA-1 clinical-trial results in HR+/HER2- advanced breast cancer, FDA-related regulatory updates, financial results, Regulation FD materials, and amendments to a loan and security agreement.
Proxy materials describe annual meeting matters, director elections, auditor ratification, executive compensation votes, stock incentive plans, and employee stock purchase plan amendments. Governance filings also record board composition changes and director compensation arrangements.
Celcuity Inc. director Polly A. Murphy reported gifting stock options linked to Celcuity common stock. On 2026-06-10, she made bona fide gift transfers totaling 28,096 stock options, each with an exercise price of $10.69 per share and an expiration date of May 19, 2035.
One transaction involved 14,048 options held indirectly through a trust, which continued to hold 14,048 options after the gift. A separate gift of 14,048 directly held options left her with zero directly held options from this grant, while she and her spouse remain trustees and beneficiaries of the trust that holds the indirect position.
Celcuity Inc. director Richard E. Buller reported a gift transfer of stock options. On the reported date, he disposed of derivative securities representing 25,006 underlying shares of common stock through bona fide gifts. After the transactions, 12,503 options are held indirectly in a trust where he and his spouse are trustees and beneficiaries, and he continues to beneficially own those securities.
Murphy Polly A. reported acquisition or exercise transactions in this Form 4 filing.
Celcuity Inc. director Polly A. Murphy received a grant of 1,530 shares of common stock in the form of restricted stock units. These RSUs vest upon the earlier of the company’s 2027 annual meeting of stockholders or April 30, 2027. Following this award, Murphy directly holds 6,530 shares of Celcuity common stock.
Dalvey David reported acquisition or exercise transactions in this Form 4 filing.
Celcuity Inc. director David Dalvey reported an equity award and updated holdings. He received a grant of 1,530 shares of common stock in the form of restricted stock units at $0.0000 per share. These units will vest upon the earlier of the 2027 annual meeting of stockholders or April 30, 2027.
After this grant, Dalvey holds 1,530 shares directly. Separately, 65,000 shares of common stock are held indirectly through Brightstone Venture Capital Fund, LP, where he is the General Partner, reflecting his associated interest in that investment vehicle.
ROMP CHARLES R reported acquisition or exercise transactions in this Form 4 filing.
Celcuity Inc. director Charles R. Romp received a grant of 1,530 shares of Common Stock in the form of restricted stock units on June 5, 2026, at no cash cost.
These restricted stock units will vest upon the earlier of the 2027 annual meeting of stockholders or April 30, 2027. After this award, Romp directly holds 1,745 shares of Celcuity common stock.
Celcuity Inc. director Richard Nigon reported an acquisition of 1,530 shares of Common Stock through a grant of restricted stock units. These units will vest upon the earlier of the 2027 annual meeting of stockholders or April 30, 2027. Following this award, he holds 80,565 shares directly.
Furcht Leo reported acquisition or exercise transactions in this Form 4 filing.
Celcuity Inc. director Leo Furcht reported a grant of 1,530 shares of common stock in the form of restricted stock units. The grant carries a zero dollar price per share, indicating it is compensation rather than a market purchase. After this award, Furcht directly holds 12,530 shares of Celcuity common stock. The restricted stock units will vest upon the earlier of the company’s 2027 annual meeting of stockholders or April 30, 2027, linking the award to his continued board service over this period.
Buller Richard E reported acquisition or exercise transactions in this Form 4 filing.
Celcuity Inc. director Richard E. Buller received a grant of 1,530 shares of Common Stock in the form of restricted stock units at no cash cost. These units will vest upon the earlier of the company’s 2027 annual meeting of stockholders or April 30, 2027.
Following this award, Buller directly holds 1,530 shares and also beneficially owns 7,789 shares of Common Stock indirectly through a trust for which he and his spouse serve as trustees and beneficiaries, according to the filing footnotes.
Celcuity Inc. completed an upsized convertible debt financing by issuing $575,000,000 aggregate principal amount of 0.250% Convertible Senior Notes due 2032, generating approximately $557.0 million in net proceeds. The company used part of this cash to voluntarily prepay and terminate its existing loan agreement, making a payoff of approximately $137.5 million including principal, interest, fees and expenses. The notes pay 0.250% interest semi-annually, mature on August 1, 2032, and are convertible at an initial rate of 8.0302 shares per $1,000 principal, implying an initial conversion price of about $124.53 per share. Celcuity may redeem the notes on or after August 6, 2029 if its stock price conditions are met, and holders have put rights upon certain fundamental changes. Remaining proceeds are earmarked for working capital, clinical and commercialization spending, and potential business or technology acquisitions.
Celcuity Inc. is offering $500,000,000 aggregate principal amount of 0.250% Convertible Senior Notes due 2032. The company expects net proceeds of approximately $484.3 million (before over-allotment) and intends to repay its term loans under the A&R Loan Agreement and use the remainder for working capital and general corporate purposes.
The notes carry an initial conversion rate of 8.0302 shares per $1,000 principal (initial conversion price of approximately $124.53 per share). Celcuity’s common stock closed at $88.95 on June 3, 2026. The offering settles on or about June 8, 2026 and includes a 30-day underwriter option for an additional $75,000,000.